Home/Day One Biopharmaceuticals/Michael Vasconelles

MV

Michael Vasconelles

Head of R&D

Day One Biopharmaceuticals

Therapeutic Areas

Oncology Pediatric Oncology Neuro-Oncology

Day One Biopharmaceuticals Pipeline

Drug	Indication	Phase
OJEMDA™ (tovorafenib)	Pediatric low-grade glioma (pLGG) with BRAF alterations	Approved
Emi-Le	Undisclosed solid tumors (Novel ADC)	Phase 1

Leadership Team at Day One Biopharmaceuticals

Chief Executive Officer, President

Chief Medical Officer

Chief Development Officer

Senior Director, Market Planning

View full Day One Biopharmaceuticals profile